Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.906
-0.041 (-4.37%)
Mar 6, 2026, 4:00 PM EST - Market closed
Biodexa Pharmaceuticals Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | 0.38 | 0.7 | 0.58 | 0.34 | Upgrade
|
| Revenue Growth (YoY) | - | - | -45.49% | 20.93% | 68.51% | -49.11% | Upgrade
|
| Cost of Revenue | 4.91 | 5.44 | 4.07 | 5.11 | 4.65 | 6.07 | Upgrade
|
| Gross Profit | -4.91 | -5.44 | -3.69 | -4.41 | -4.08 | -5.73 | Upgrade
|
| Selling, General & Admin | 4.14 | 3.79 | 3.03 | 4.54 | 2.95 | 4.96 | Upgrade
|
| Other Operating Expenses | -0.06 | -0.03 | -0.01 | -0.02 | -0.02 | -0.01 | Upgrade
|
| Operating Expenses | 4.08 | 3.76 | 3.02 | 4.52 | 2.92 | 4.95 | Upgrade
|
| Operating Income | -8.99 | -9.2 | -6.7 | -8.93 | -7 | -10.67 | Upgrade
|
| Interest Expense | -0.25 | -0.17 | -0.04 | -0.05 | -0.04 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.11 | 0.17 | 0.08 | 0.03 | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.61 | 3.22 | 0.49 | 0.47 | 0.94 | -0.4 | Upgrade
|
| EBT Excluding Unusual Items | -6.52 | -5.98 | -6.18 | -8.49 | -6.11 | -11.1 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -2.29 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -10.08 | Upgrade
|
| Other Unusual Items | - | - | -1.31 | - | - | - | Upgrade
|
| Pretax Income | -6.52 | -5.98 | -7.49 | -8.49 | -6.11 | -23.47 | Upgrade
|
| Income Tax Expense | -0.29 | -0.25 | -0.41 | -0.83 | -0.65 | -1.28 | Upgrade
|
| Earnings From Continuing Operations | -6.23 | -5.73 | -7.08 | -7.66 | -5.46 | -22.19 | Upgrade
|
| Net Income | -6.23 | -5.73 | -7.08 | -7.66 | -5.46 | -22.19 | Upgrade
|
| Net Income to Common | -6.23 | -5.73 | -7.08 | -7.66 | -5.46 | -22.19 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | - | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - | Upgrade
|
| EPS (Basic) | -39.05 | -115.67 | - | - | - | - | Upgrade
|
| EPS (Diluted) | -39.05 | -115.67 | - | - | - | - | Upgrade
|
| Free Cash Flow | -10.77 | -12.27 | -6.85 | -7.11 | -6.33 | -9.51 | Upgrade
|
| Free Cash Flow Per Share | -67.53 | -247.74 | - | - | - | - | Upgrade
|
| Operating Margin | - | - | -1759.58% | -1277.83% | -1210.73% | -3111.08% | Upgrade
|
| Profit Margin | - | - | -1858.01% | -1095.28% | -944.64% | -6469.10% | Upgrade
|
| Free Cash Flow Margin | - | - | -1798.42% | -1017.17% | -1094.81% | -2772.60% | Upgrade
|
| EBITDA | -8.87 | -9.08 | -6.56 | -8.76 | -6.79 | -9.57 | Upgrade
|
| D&A For EBITDA | 0.12 | 0.12 | 0.14 | 0.17 | 0.21 | 1.1 | Upgrade
|
| EBIT | -8.99 | -9.2 | -6.7 | -8.93 | -7 | -10.67 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.